Litcius/Paper detail

[<sup>161</sup>Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [<sup>177</sup>Lu]Lu-PSMA-617

Andrea Schaefer-Schuler, Caroline Burgard, Arne Blickle, Stephan Maus, Christine Petrescu, Sven Petto, Mark Bartholomä, Tobias Stemler, Samer Ezziddin, Florian Rosar

2024Theranostics48 citationsDOIOpen Access PDF

Abstract

Tb as a promising radionuclide for PSMA-RLT in mCRPC.

Topics & Concepts

MedicineDosimetryNuclear medicineProstate cancerAbsorbed doseRadioligandRadioimmunotherapyRadionuclide therapyProstateUrologyInternal medicineCancerReceptorMonoclonal antibodyImmunologyAntibodyProstate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and ApplicationsMass Spectrometry Techniques and Applications
[<sup>161</sup>Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [<sup>177</sup>Lu]Lu-PSMA-617 | Litcius